Wedbush reiterated their top pick rating on shares of Ascendis Pharma (NASDAQ:ASND) in a research note issued to investors on Friday morning. The brokerage currently has a $76.00 price objective on the biotechnology company’s stock.
Other equities research analysts have also recently issued reports about the stock. BidaskClub raised shares of Ascendis Pharma from a hold rating to a buy rating in a report on Wednesday, December 27th. Zacks Investment Research raised shares of Ascendis Pharma from a strong sell rating to a hold rating in a report on Wednesday, February 21st. Leerink Swann reaffirmed a market perform rating and issued a $64.00 target price (up from $37.00) on shares of Ascendis Pharma in a report on Monday, April 2nd. ValuEngine raised shares of Ascendis Pharma from a hold rating to a buy rating in a report on Monday, April 2nd. Finally, HC Wainwright reaffirmed a buy rating on shares of Ascendis Pharma in a report on Friday, January 19th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $67.33.
Shares of NASDAQ:ASND opened at $61.18 on Friday. Ascendis Pharma has a one year low of $21.95 and a one year high of $69.00. The stock has a market capitalization of $2,649.63, a PE ratio of -14.72 and a beta of 0.63.
ILLEGAL ACTIVITY NOTICE: “Ascendis Pharma (ASND) Earns Top Pick Rating from Wedbush” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://weekherald.com/2018/04/24/ascendis-pharma-asnd-earns-top-pick-rating-from-wedbush.html.
About Ascendis Pharma
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.
Receive News & Ratings for Ascendis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.